Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency

Nature Medicine

Volumn 4, Issue 7, 1998, Pages 802-807

  Tang, Binwu ^a   Böttinger, Erwin P ^a,b   Jakowlew, Sonia B ^a   Bagnall, Kerri M ^a   Mariano, Jennifer ^a   Anver, Miriam R ^c   Letterio, John J ^a   Wakefield, Lalage M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CHEMICAL CARCINOGENESIS; GENE DELETION; GROWTH INHIBITION; HAPLOIDY; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RNA ANALYSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CARCINOGENICITY TESTS; CELL CYCLE PROTEINS; CELL DIVISION; GENE TARGETING; GENES, TUMOR SUPPRESSOR; LIVER; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 2642614530     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0798-802     Document Type: Article

References (45)

1. Roberts, A.B. & Sporn, M.B. in: Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors Vol 95/1 (eds. Sporn, M.B. & Roberts, A.B) 419-472 (Springer-Verlag, Berlin, 1990).
2. Sporn, M.B. & Roberts, A.B. Autocrine growth factors and cancer. Nature 313, 745-747 (1985).
3. Fynan, T.M. & Reiss, M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncog. 4, 493-540 (1993).
4. Brattain, M.G., Markowitz, S.D. & Willson, J.K. The type II transforming growth factor-ß receptor as a tumor-suppressor gene. Curr. Opin. Oncol. 8, 49-53 (1996).
5. Markowitz, S. et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338 (1995).
6. Hahn, S.A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996).
7. De Souza, A.T., Hankins, G.R., Washington, M.K., Orton, T.C. & Jirtle, R.L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genet. 11, 447-449 (1995).
8. Wu, S.P. et al. TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J. Cell Biol. 116, 187-196 (1992).
9. Huang, F., Newman, E., Theodorescu, D., Kerbel, R.S. & Friedman, E. Transforming growth factor β1 (TGFβ1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF-β1 antisense expression plasmid. Cell Growth Differ. 6, 1635-1642 (1995).
10. Gorsch, S.M., Memoli, V.A., Stukel, T.A., Gold, L.I. & Arrick, B.A. Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 52, 6949-6952 (1992).
11. Tsushima, H. et al. High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110, 375-382 (1996).
12. Fearon, E.R. Human cancer syndromes: clues to the origin and nature of cancer. Science 278, 1043-1050 (1997).
13. Kulkarni, A.B. et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90, 770-774 (1993).
14. Shull, M.M. et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
15. Carr, B.I., Hayashi, I., Branum, E.L. & Moses, H.L. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type β transforming growth factor. Cancer Res. 46, 2330-2334 (1986).
16. Russell, W.E., Coffey, R.J.,Jr., Ouellette, A.J. & Moses, H.L. Type β transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc. Natl. Acad. Sci. USA 85, 5126-5130 (1988).
17. Oberhammer, F.A. et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc. Natl. Acad. Sci. USA 89, 5408-5412 (1992).
18. Evan, G.I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128 (1992).
19. Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295-300 (1992).
20. Naik, P., Karrim, J. & Hanahan, D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev. 10, 2105-2116 (1996).
21. Crocker, T.T., Teeter, A. & Nielsen, B. Postnatal cellular proliferation in mouse and hamster lung. Cancer Res. 30, 357-361 (1970).
22. Ravitz, M.J. & Wenner, C.E. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-β. Adv. Cancer Res. 71, 165-207 (1997).
23. Iavarone, A. & Massagué, J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 387, 417-422 (1997).
24. Border, W.A. & Ruoslahti, E. Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest. 90, 1-7 (1992).
25. Nathan, C. & Sporn, M. Cytokines in Context. J. Cell Biol. 113:5, 981-986 (1991).
26. Diwan, B.A., Rice, J.M., Ward, J.M., Ohshima, M. & Lynch, P.H. Inhibition by phenobarbital and lack of effect of amobarbital on the development of liver tumors induced by N-Nitrosodiethylamine in juvenile B6C3F1 mice. Cancer Lett. 23, 223-234 (1984).
27. Glick, A.B. et al. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc. Natl. Acad. Sci. USA 90, 6076-6080 (1993).
28. Glick, A.B. et al. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev. 8, 2429-2440 (1994).
29. 1 arrest, p53 and Rb. Cancer Res. 56, 3645-3650 (1996).
30. Cui, W. et al. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531-542 (1996).
31. Torre-Amione, G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87, 1486-1490 (1990).
32. Fajardo, L.F., Prionas, S.D., Kwan, H.H., Kowalski, J. & Allison, A.C. Transforming growth factor β1 induces angiogenesis in vivo with a threshold pattern. Lab. Invest. 74, 600-608 (1996).
33. Markowitz, S.D. & Roberts, A.B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev. 7, 93-102 (1996).
34. Böttinger, E.P., Jakubczak, J.L., Haines, D.C., Bagnall, K. & Wakefield, L.M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthrancene. Cancer Res. 57, 5564-5570 (1997).
35. Maroulakou, I.G., Anver, M., Garett, L., & Green, J.E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 91, 11236-11240 (1994).
36. Tashiro, H. et al. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron. Artery Dis. 8, 143-147 (1997).
37. Cambien, F. et al. Polymorphisms of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28, 881-887 (1996).
38. Langdahl, B.L., Knudsen, J.Y., Jensen, H.K., Gregersen, N. & Eriksen, E.F. A sequence variation: 713-8delC in the transforming growth factor-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 20, 289-294 (1997).
39. Firth, C.H., Ward, J.M & Turuson, V.S. in Pathology of Tumors in Laboratory Animals. Vol.2. Tumours of the Mouse, 2nd edn. (eds. V. Turosoy & U. Mohr) 223-269 (IARC Scientific Publications, 1984).
40. Rehm, S., Werd, J.M. & Sabs, B. in Pathology of Tumors in Laboratory Animals. Vol.2. Tumours of the Mouse, 2nd edn. (eds. V. Turosov & U. Mohr) 325-355 (IARC Publications, Lyon, France, 1984).
41. Danielpour, D. & Roberts, A.B. Specific and sensitive quantitation of transforming growth factor β3 by sandwich enzyme-linked immunosorbent assay. J. Immunol. Methods 180, 265-272 (1995).
42. Danielpour, D. et al. Sandwich enzyme-linked immunosorbent assays (SELISAs) quantitate and distinguish two forms of transforming growth factor-β (TGF-β1 and TGF-β2) in complex biological fluids. Growth Factors 2, 61-71 (1989).
43. Church, G.M. & Gilbert, W. Genomic sequencing. Proc. Natl. Acad. Sci. USA 81, 1991-1995 (1984).
44. Jakowlew, S.B., Moody, T.W., You, L. & Mariano, J.M. Reduction of transforming growth factor-β type II receptor in mouse lung carcinogenesis. Mol. Carcinog. 22, 46-56 (1998).
45. Flanders, K.C. et al. Transforming growth factor-β1: histochemical localization with antibodies to different epitopes. J. Cell Biol. 108, 653-660 (1989).